FDA Approves New Tablet Form of Evrysdi for Treatment of Spinal Muscular Atrophy
The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...
Ionis Pharma stock hits 52-week low at $30.86
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stock has reached a new 52-week low, touching down at $30.86, with InvestingPro data showing the stock trading at $30.89, significantly below its 52-week high ...
SMA1d
Spinraza treatment won’t lead to kidney dysfunction, per study
Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...
Biogen stock hits 52-week low at $139.7 amid challenges
Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...